Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Birth order

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    382 result(s) found for: Birth order. Displaying page 9 of 20.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2008-008238-35 Sponsor Protocol Number: AMLSG11-08 Start Date*: 2009-06-24
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Co...
    Medical condition: Newly diagnosed core binding factor acute myeloid leukemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005769-36 Sponsor Protocol Number: GS-EU-177-0111 Start Date*: 2009-01-15
    Sponsor Name:Gilead Sciences Limited
    Full Title: A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovi...
    Medical condition: Antiretroviral-experienced HIV 1 infected subjects on their first and stable HAART regimen of efavirenz, emtricitabine, and tenofovir DF.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003547-29 Sponsor Protocol Number: 04-22 Start Date*: 2012-10-17
    Sponsor Name:Onconova Therapeutics Inc.
    Full Title: A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metas...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004093-27 Sponsor Protocol Number: ML20493 Start Date*: 2007-04-04
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: A multicenter, phase II, open-label study evaluating the benefit of addition of MabThera (rituximab) to standard chemotherapies in patients with previously untreated mantle cell lymphoma.
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-005002-30 Sponsor Protocol Number: ICORG09-13 Start Date*: 2012-01-05
    Sponsor Name:ICORG-the All Ireland co-operative Oncology Research group
    Full Title: Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.
    Medical condition: Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005887-24 Sponsor Protocol Number: GEMCAD-2103//MO44170 Start Date*: 2022-11-25
    Sponsor Name:Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD)
    Full Title: Phase II study of Atezolizumab plus Tiraglolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal
    Medical condition: Locallized squamous cell carcinoma of the anal canal in the first-line setting.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002141 Anal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000206-38 Sponsor Protocol Number: 54767414MMY3012 Start Date*: 2017-10-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) ES (Ongoing) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001959-19 Sponsor Protocol Number: P05122 Start Date*: 2008-03-19
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti- Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Med...
    Medical condition: Persistent Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001099-31 Sponsor Protocol Number: I5B-MC-JGDP Start Date*: 2017-05-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
    Medical condition: First-Line Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073364 Ductal adenocarcinoma of pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003592-19 Sponsor Protocol Number: NEOPAX-001 Start Date*: 2012-12-11
    Sponsor Name:CUB Erasme Hospital
    Full Title: Evaluation of tumoral perfusion modification by dynamic imaging after chemotherapy combining gemcitabine and nab-paclitaxel (Abraxane) in patients with potentially operable, locally advanced or met...
    Medical condition: Resectable (cohort 1) and locally advanced or metastatic (cohort 2) pancreatic ductal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005314-12 Sponsor Protocol Number: WX/60-004 Start Date*: 2007-01-05
    Sponsor Name:Wilex AG
    Full Title: A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to ev...
    Medical condition: Locally advanced, non-resectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002502-34 Sponsor Protocol Number: VO42.05 Start Date*: 2005-12-05
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as al...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) DE (Completed) DK (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013638-26 Sponsor Protocol Number: UCL/08/0359 Start Date*: 2011-08-24
    Sponsor Name:University College London
    Full Title: A phase I/II study of first line Vorinostat with pemetrexed-cisplatin, in patients with malignant pleural mesothelioma
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004315-13 Sponsor Protocol Number: CIGE025AMX02 Start Date*: 2017-05-08
    Sponsor Name:Novartis
    Full Title: Multicentric, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12-MonthPeriod, in Patients with Severe IgE-mediated Asthma Inadequately Controlled...
    Medical condition: Difficult to control severe asthma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003094-15 Sponsor Protocol Number: V98_06E1 Start Date*: 2016-02-11
    Sponsor Name:GlaxoSmithKline Biologicals S.A.
    Full Title: A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subj...
    Medical condition: Healthy person immune response to a second dose of Group B Streptococcus polysaccharide capsule antigens
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10053588 Group B streptococcus neonatal sepsis PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004948-11 Sponsor Protocol Number: E2020-A001-335 Start Date*: 2017-03-09
    Sponsor Name:Eisai Inc.
    Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D...
    Medical condition: Down Syndrome, Cognitive Dysfunction
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023099-13 Sponsor Protocol Number: V00251 ST 201 1A Start Date*: 2011-01-31
    Sponsor Name:PIERRE FABRE MEDICAMENT -IRPF- PIERRE FABRE INNOVATION
    Full Title: V0251 oral suspension efficacy and tolerance in vestibular neuritis. A randomised double-blind placebo controlled study
    Medical condition: The aim of this exploratory study is to assess the efficacy of the L-enantiomer V0251 oral form in the treatment of acute episodes of vertigo.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047393 Vestibular neuronitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000046-21 Sponsor Protocol Number: C0524T03 Start Date*: 2004-11-22
    Sponsor Name:Centocor BV
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Su...
    Medical condition: Severe persistent asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Prematurely Ended) SE (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000042-37 Sponsor Protocol Number: GHNOO-1658 Start Date*: 2005-07-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit
    Medical condition: Noonan syndrome associated short stature
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029748 PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003659-19 Sponsor Protocol Number: R317573DEP2002 Start Date*: 2006-09-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiet...
    Medical condition: Anxiety disorders and depression
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057666 Anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 03:29:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA